Akebia Therapeutics (AKBA) said Tuesday it has dosed the first patient in a phase 2 trial of its experimental drug, praliciguat, for the treatment of a rare kidney disease.

The company said the study will assess the safety and efficacy of the drug in about 60 adults with the condition who are already being treated with standard treatment.

Akebia said the primary endpoint of the study is the change from baseline in the urine protein-to-creatinine ratio, a key marker of kidney damage. A key secondary endpoint is the percentage of patients achieving partial remission, the company added.